FACTBOX-AstraZeneca's potential coronavirus vaccine

* For FACTBOX on vaccines and treatments, click: (Updates with Latin America and Japan deals) Aug 13 (Reuters) - Argentina and Mexico will produce the AstraZeneca COVID-19 vaccine for most of Latin America, Argentine President Alberto Fernandez said on Wednesday Drugmakers are racing to combat the pandemic that has killed about 750,000 people and infected more than 20 million. There are no approved vaccines for COVID-19, but AstraZeneca's shot is widely seen as one of the leading candidates. The company has been granted protection from future product liability claims related to the vaccine by most of the countries with which it has so far struck supply agreements, a senior executive told Reuters. Below are the main details of AstraZeneca's coronavirus vaccine hopeful and its supply and production deals. TYPE * The shot, called AZD1222 or ChAdOx1 nCoV-19, is a recombinant viral vector vaccine developed by Oxford University. * It was licensed to AstraZeneca in April. * The vaccine candidate uses a weakened version of a common-cold virus that encodes instructions for making proteins from the novel coronavirus to build immunity. PROTECTION DURATION * The shot is likely to provide protection for about a year, and the company is leaning towards a two-dose strategy for the potential vaccine. EXPECTED COST * AstraZeneca says it will be able to manufacture the vaccine at a few dollars per dose. * According to Italy's health ministry, an AZD1222 shot would cost about 2.5 euros ($2.8) per dose in Europe. * India's Serum Institute said it will price the shot at $3 per dose for the country and other emerging economies. * AstraZeneca has said it does not expect to profit from the vaccine candidate during the pandemic. * Costs in other regions have not been disclosed. TRIALS * AstraZeneca's CEO said good data has come in so far on the shot, after early-stage clinical trials showed it was safe and produced an immune response. * Late-stage trials are currently underway in Britain, Brazil and South Africa, and are due to start in the United States in the third quarter. * Talks are ongoing with Mexico, and reports have said the Indian regulator has also given a nod for mid-to-late-stage trials. TIMELINE * The vaccine could be rolled out by year-end, but there is no certainty of that, its lead developer said in July. * Data from late-stage studies is expected by August to September. * Delivery of the first doses is expected between September and October. * Experts predict a safe and effective vaccine could take 12-18 months to develop. TARGET DOSES * More than 2.4 billion TIE-UPS * With U.S. backing, AstraZeneca has tied up with IQVIA to speed up trials. Even before conclusive evidence of the vaccine's success or failure, AstraZeneca has signed other deals to produce and supply the shot. MANUFACTURING DEALS (Most recent first) FIRM BASED IN DEAL VALUE FOR FURTHER Foundation Mexico Unknown Latin [nL1N2FF of Mexican American 01U] billionaire supply with Carlos Slim Argentina, excluding Brazil mAbxience of Argentin Unknown Initially [nL1N2FF the INSUD a producing 150 01U] Group million doses for Latin America, excluding Brazil Kangtai Bio China Unknown Annual [nL4N2F8 production 2GT] capacity of at least 100 million doses this year, and at least 200 million doses by the end of next year Emergent U.S. $174 Undisclosed [nL3N2EY BioSolutions million doses 2LF] SK South Unknown Undiluted [nL3N2ES Bioscience Korea solutions of 288] the vaccine R-Pharm Russia Unknown Unkown doses [nL5N2EO 2S4] Daiichi Japan Unknown Unkown doses [nL4N2E3 Sankyo 19J] Fundação Brazil $127 About 30 [nL1N2E4 Osvaldo Cruz million million doses 03I] (Fiocruz) Symbiosis Scotland Undisclosed Clinical [nL4N2E1 Pharmaceutic trial supply 2U2] al Cobra U.S. Undisclosed One million [nL8N2DT Biosciences doses per 1YB] month Catalent U.S. Undisclosed Vial filling [nL4N2DS and packaging 2XW] Emergent U.S. $87 million 300 million [nL4N2DO BioSolutions doses 2U1] Serum India Undisclosed One billion [nL4N2DH Institute of doses for low 3LY] India and middle-income countries, with 400 million before end of 2020 Oxford UK Undisclosed Undisclosed [nL4N2DL Biomedica doses 1B3] SUPPLY DEALS (Most recent first) REGION/FIRM DOSES FUNDING DELIVERIES FURTHER Latin Initiall Unknown First half of [nL1N2FF America, y 150 from Mexico 2021 01U] excluding million and Brazil doses, Argentina could extend to 250 million Japan 120 Undisclosed 30 million [nL4N2F9 million doses by 2XN] doses March 2021 Israel Unknown Unknown Unknown [nL5N2ER 4TW] Brazil Possibly Unknown Unknown [nL1N2FE more 1O2] than 100 million France, 300 750 million By end of [nL8N2DQ Germany, million, euros for 2020 0GG] Italy and with 300 mln the option Netherlands of under addition Inclusive al 100 Vaccines million Alliance (IVA) Italy (part 75 185 million By end of [nL8N2DS of IVA) million euros 2020 2XO] Serum One Unknown 400 million [nL4N2DH Institute of billion, before the 3LY] India unspecif end of 2020 ied number of doses will go to India Epidemic 300 $750 Some before [nFWN2DH response million million, end of 2020 0DK] group CEPI with $383 and Vaccine from CEPI alliance GAVI United 300 $1.2 By Oct [nL4N2D3 States million billion 1M3] United 100 Unknown By Sept/Oct [nRSU597 Kingdom million 2Na] AstraZeneca is also in talks with Spain. Sources: Reuters reporting, press releases ($1 = 0.8850 euros) ($1 = 0.8156 pounds) (Reporting by Pushkala Aripaka in Bengaluru; Additional reporting by Tanishaa Nadkar; Editing by Jason Neely, Nick Macfie, Sherry Jacob-Phillips and Jan Harvey)